Shop Now Contact

Anti-Human NGF (Tanezumab Biosimilar)

Cat # Size Price Quantity
5059011 mg$190
5059025 mg$480
50590320 mg$1200

  Bulk/Custom

Product Details

CloneTanezumab
ApplicationNeutralization, Intracellular Flow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionTanezumab Biosimilar, Human NGF Monoclonal Antibody
IsotypeHuman IgG2
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman NGF
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Min Sample Size1 mg
Storage Conditions4ºC
Maximal Shelf Life12 months
Target NameNGF
Research AreasNeurons, Cancer Marker
See All FormatsClone Tanezumab

Background Information

Tanezumab is a humanized monoclonal antibody of the immunoglobulin G2 (IgG2) subclass that selectively binds to and neutralizes nerve growth factor (NGF), a key neurotrophin involved in neuronal growth, survival, and pain signal modulation. Structurally, Tanezumab is a recombinant glycoprotein with a molecular weight of approximately 150 kilodaltons (kDa). The molecule is composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds, forming the characteristic Y-shaped antibody configuration. It is produced in mammalian cell expression systems, such as Chinese Hamster Ovary (CHO) cells, which ensure accurate folding, glycosylation, and overall structural stability consistent with human antibodies.

The antigen-binding fragments (Fab) of Tanezumab contain variable domains (VH and VL) whose complementarity-determining regions (CDRs) define high-affinity and specificity for NGF. These CDRs engage discrete epitopes on NGF through hydrogen bonding, van der Waals interactions, and hydrophobic contacts, yielding nanomolar-range binding affinities. By binding directly to NGF, Tanezumab prevents NGF from interacting with its cognate receptors: tropomyosin receptor kinase A (TrkA) and the low-affinity p75 neurotrophin receptor (p75NTR). This blockade disrupts the receptor-mediated signaling cascades that regulate the activation of downstream pathways, such as the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)-AKT pathways, which influence nociceptor sensitization and neuronal growth responses in experimental systems.

The Fc (fragment crystallizable) region of Tanezumab, characteristic of the IgG2 subclass, contributes to its structural integrity and extended half-life through binding to the neonatal Fc receptor (FcRn), which protects the molecule from lysosomal degradation. Unlike IgG1 antibodies, IgG2 has limited effector function, reducing complement activation and receptor-mediated immune responses. Overall, Tanezumab exemplifies advanced antibody engineering designed for targeted ligand sequestration—combining high molecular precision, biophysical stability, and selective interference with neurotrophin signaling for mechanistic studies of neuronal pathway regulation.

Data Sheets

Anti-Human NGF (Tanezumab Biosimilar) TDS

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.